• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

4.540 -0.080 (-1.73%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
January 12, 2026
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
November 12, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Changes to Its Board of Directors
September 03, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
August 11, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
July 24, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
July 14, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
May 16, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
May 15, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Pricing of $16 Million Offering
May 15, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
May 05, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
March 07, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
January 27, 2025
From The Schall Law Firm
Via Business Wire
News headline image
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
January 21, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
January 16, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
November 27, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
November 13, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
November 12, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Sidoti Events, LLC's Virtual November Micro-Cap Conference
November 12, 2024
Via ACCESSWIRE
News headline image
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
November 05, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces $36 Million Registered Direct Offering
September 03, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
August 12, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
July 17, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
July 03, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
June 21, 2024
From Atara Biotherapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap